Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. - Klement,G.; Baruchel,S.; Rak,J.; Man,S.; Clark,K.; Hicklin,D.J.; Bohlen,P.; Kerbel,R.S. (J Clin Invest, 2000)